SCHEMBL369532

SCHEMBL369532

CCOC(=O)C(Br)C(=O)c1cn(Cc2ccc(OC)cc2)nc1C(O)CC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.37
MEN1 O00255 3/20 0.37
PDE4D Q08499 1/20 0.36
MAPT P10636 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
EPHX2 P34913 1/20 0.36
CACNA1G O43497 2/20 0.36
CACNA1H O95180 2/20 0.36
CACNA1I Q9P0X4 2/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 2/20 0.35
UCHL1 P09936 1/20 0.35
GLA P06280 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HDAC1 Q13547 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12482396 0.90 KMT2A (0.41) KMT2AMEN1AADATCACNA1GCACNA1H
SCHEMBL370871 0.84 LDHA (0.42) KMT2AMEN1AADATCACNA1GCACNA1H
SCHEMBL369329 0.84 KMT2A (0.42) KMT2AMEN1AADATCACNA1GCACNA1H
SCHEMBL370870 0.84 CACNA1G (0.40) KMT2AMEN1PDE4DMAPTAADAT
SCHEMBL368607 0.79 CACNA1G (0.41) KMT2AMEN1AADATCACNA1GCACNA1H
SCHEMBL369533 0.79 CACNA1G (0.39) KMT2AMEN1AADATCACNA1GCACNA1H
SCHEMBL369424 0.74 UCHL1 (0.47) KMT2AMEN1PDE4DMAPTUCHL1
SCHEMBL369164 0.74 ALDH1A1 (0.48) KMT2APDE4DMAPTAADATNPC1
SCHEMBL3356514 0.74 MAPT (0.46) KMT2AMEN1PDE4DMAPTUCHL1
SCHEMBL369360 0.73 MAPT (0.47) KMT2AMEN1PDE4DMAPTCACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KMT2A 1638/4885MEN1 4328/4885PDE4D 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.